Yoshitake, H., Negoto, T., Moritsubo, M., Furuta, T., Jo, M., Hirota, T., Sakata, K., Nakamura, H. and Morioka, M. Chromosomal instability is associated with paradoxical cGAS upregulation and impaired STING signaling shaping the immune microenvironment in glioblastoma.
Neurooncol. Adv., vdag179 (2026) |
Hara, T., Meng, S., Konno, M., Nishida, N., Koseki, J., Meguro, K., Kawano, Y., Morie, T., Dan, S., Satoh, T., Akai, S., Tsujikawa, K., Eguchi, H., Mori, M., Miura, Y., Nishiyama, N. and Ishii, H. Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects.
Cancer Med., 15, e72058 (2026) |
Ozaki, H., Sasaki, N. and Kitajima, S. An aminoacyl-tRNA synthetase governs dsRNA-mediated trade-off between longevity and innate immunity.
Mol. Cell, 86, 2237-2239 (2026) |
Kamakura, N., Jo, M., Takahashi, M. and Hirota, T. Targeting cell cycle vulnerabilities in cancers: Emerging strategies for therapeutic development.
Cancer Sci., in press (2026) |
Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., Katayama, R. and Ohashi, K. Afatinib overcomes osimertinib resistance via Egfr v804f mutation in a syngeneic Egfr-mutant lung cancer mouse model.
Cancer Sci., in press (2026) |
Nagasaka, M., Facchinetti, F., Bigot, L., Brayé, F., Groves, M. R., Yosa, J., Wekken, A. V., Aldea, M., Besse, B., Planchard, D., Naltet, C., Katayama, R., Olaussen, K. A., Loriot, Y. and Friboulet, L. The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
npj Precis. Oncol., in press (2026) |
Kurosaki, T., Suzuki, S., Watanabe, Y., Kenmotsu, H., Itoh, S., Yamaguchi, M., Shiono, A., Suzuki, T., Yokoyama, T., Toi, Y., Tanaka, H., Oki, M., Tsuda, T., Ichihara, E., Azuma, K., Tanaka, H., Arai, R., Uchibori, K., Miyauchi, E., Katayama, R. and Hayashi, H. Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Lung Cancer, 216, 109416 (2026) |
Suenaga, M., Mashima, T., Kawata, N., Dan, S., Seimiya, H. and Yamaguchi, K. Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
ESMO Gastrointest. Oncol., 12, 100323 (2026) |
Kawamoto, S., Horiguchi, H., Torigoe, D., Wakita, M., Ito, K., Sugawara, S., Zhou, X., Mikawa, T., Park, J. H., Jung, B. K., Okumura, Y., Miyagawa, H., Maruya, M., Hori, N., Uemura, K., Sugimoto, M., Matsuda, M., Mochizuki, N., Kondoh, H., Takahashi, A., Oike, Y. and Hara, E. Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor.
EMBO Rep., in press (2026) |
Sakiyama, K., Kumegawa, K., Yang, L., Tanabe, M. and Maruyama, R. Long-term intermittent estradiol exposure induces epithelial-mesenchymal transition-like plasticity in MCF10A cells.
Biochem. Biophys. Res. Commun., 812, 153601 (2026) |
